Amgen stock falls on BMO downgrade and Novartis trial setback
Published on 09/08/2026 at 17:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Amgen Inc. stock (ISIN US0311621009) came under marked pressure on September 8, 2026, with shares indicated around USD 416.88 in premarket trading on Nasdaq, down roughly 4.7 percent from the prior close as investors reacted to a BMO Capital rating downgrade and fresh data from a Novartis cardiovascular drug trial.Yahoo Finance At the premarket level of USD 416.88, the stock was trading below its recent 52-week high of USD 447.03, highlighting a pullback after a strong run earlier in the year.Yahoo Finance
Analyst downgrade and rival trial drive the move
The immediate catalyst for Amgen stock on September 8, 2026 was a rating change from BMO Capital, which lowered its recommendation on the shares from Outperform to Market Perform while maintaining a price target of USD 450.00 for the biotech group.Yahoo Finance According to market commentary, that shift in stance added to valuation concerns after a period of robust share performance, and it contributed to intraday declines of around 8 percent when the stock traded near USD 402.07 at 10:04 Eastern Time on September 8, 2026, versus the prior close, according to trading data summarized by TickerSpark.TickerSpark
Sentiment was further influenced by clinical news from rival Novartis. A Phase III trial of Novartis’s experimental lipoprotein(a)-lowering treatment, pelacarsen, did not show a reduction in major cardiovascular events despite achieving the targeted lipid reductions, a setback that rippled through the broader Lp(a) drug race and prompted a sector-wide reassessment of risk.CNBC Coverage noted that Amgen shares fell about 5 percent in extended trading on the preceding trading day as investors digested the implications for competing candidates such as Amgen’s own Lp(a)-focused agent.CNBC For shareholders, the combination of a high starting valuation, a downgrade and trial uncertainty turned a previously supportive narrative into a more cautious one.
Recent share performance and valuation tensions
Despite the latest setback, Amgen stock has delivered strong performance over the past year. A discounted cash flow analysis published on September 8, 2026 by GuruFocus highlighted that the shares had gained about 36.3 percent year to date and 58.4 percent over the past twelve months as of a cash-flow review using a spot price of USD 437.23.GuruFocus That same analysis compared the prevailing share price with an earnings-based intrinsic value estimate of USD 295.98 and a free-cash-flow-based intrinsic value of USD 216.27, concluding that the stock looked significantly overvalued relative to both metrics, with a negative margin of safety of roughly 47.7 percent versus the earnings-based figure.GuruFocus
The valuation debate is further sharpened by a GF Value benchmark of USD 365.80 cited in the same report, which again sits below the high-USD 430 to USD 440 trading range seen in recent days.GuruFocus In other words, multiple models in that analysis suggest that Amgen’s share price is 19 to 25 percent above a range of intrinsic value estimates, underscoring why some analysts and investors may be more sensitive to any new risk in the pipeline or competitive landscape. For investors, this means that downside reactions to adverse news could be amplified when a stock is priced above conservative valuation measures.
Fundamentals: latest quarterly results frame the story
Beyond daily price moves, the fundamental backdrop for Amgen remains anchored in its most recent quarterly figures. According to a summary of the company’s second quarter 2026 financial results dated August 4, 2026, Amgen reported Q2 2026 revenue and earnings that represented its latest officially published interim performance.Zonebourse While detailed line items are not fully visible in the recent snippets, the Q2 2026 report is identified as the most current quarter, and thus serves as the relevant baseline within the freshness window defined relative to September 8, 2026.Zonebourse In the context of the DCF review, the company’s strong cash generation and profitability underpin the long-term valuation models that nonetheless flag overvaluation at recent prices.GuruFocus
The combination of rising reported earnings and revenue in recent quarters and the high share-price performance explains why valuation-focused research now stresses the gap between fundamentals and market pricing. When a stock has climbed more than 50 percent over twelve months and trades materially above intrinsic value estimates, even a relatively modest negative clinical readout or rating downgrade can trigger a sharper share-price reaction than it might have earlier in the rally.
Analyst views and sector context
In parallel to the BMO Capital downgrade, broader analyst coverage paints a mixed picture. A same-day note from Cantor Fitzgerald reiterated a Neutral rating on Amgen with a price target of USD 400.00, positioning the stock roughly in line with the intraday level around USD 402.07 observed on September 8, 2026 and below the USD 450.00 target maintained by BMO.MarketBeat Aggregated data show that one analyst currently rates the shares as Strong Buy, twelve as Buy, fourteen as Hold and three as Sell, leading to an overall average rating of Hold and an average target price of USD 381.68 based on recent coverage.MarketBeat
This distribution of opinions illustrates both the appeal and perceived risk of Amgen at current levels. Some analysts see continued upside from the company’s biologics, oncology and cardiovascular pipeline, while others emphasize the stretched valuation and the uncertainties highlighted by the Novartis pelacarsen trial outcome. In addition, sector performance data on September 8, 2026 show that Amgen’s roughly 8.33 percent decline, as referenced in intraday sector analysis, significantly underperformed a Pharmaceuticals and Medical Research sector move of about negative 2.43 percent on the same day.Mitrade That relative underperformance suggests that the market reaction was driven more by stock-specific catalysts than by broad sector weakness.
Key risk: cardiovascular pipeline uncertainty
The most visible risk factor tied to the current move is the broader uncertainty in the cardiovascular drug pipeline focused on lipoprotein(a). Commentary on September 8, 2026 highlighted that the Novartis trial’s failure to reduce major cardiovascular events, despite lowering Lp(a) levels, raised questions about the translation of biomarker success into clinical outcomes.CNBC Since Amgen is also advancing an Lp(a)-targeting candidate in Phase III, investors are now more alert to the possibility that similar mechanistic challenges could affect future trial readouts, even if the molecules and study designs differ.
This uncertainty does not immediately change Amgen’s current revenue base, which is still dominated by its established biologics portfolio, but it does inject more caution into expectations for future growth from the cardiovascular franchise. For valuation models that had assumed robust incremental cash flows from such pipeline assets, a higher perceived risk can reduce implied intrinsic value, thereby widening the apparent gap between price and fundamental estimates. Accordingly, pipeline outcome risk now stands alongside general valuation risk as a central counter-factor for investors assessing Amgen stock at elevated levels.
Representative product: Tezspire expands specialty portfolio
One recent product event that underscores Amgen’s broader specialty pipeline is Tezspire, a biologic therapy co-developed with AstraZeneca for severe asthma and related indications. A release dated August 27, 2026 reported that Tezspire demonstrated positive Phase III results in eosinophilic esophagitis across both co-primary and all key secondary endpoints in a late-stage study, marking a clinical milestone for this medicine.Zonebourse While the detailed numerical outcomes are not fully visible in the snippet, the clear statement that the trial met its co-primary endpoints indicates a robust efficacy profile in the tested population.
For Amgen, such results help diversify its pipeline beyond cardiovascular risk and support a narrative of multi-franchise innovation. Successful Phase III outcomes in conditions like eosinophilic esophagitis can translate into new revenue streams once regulatory approvals are secured, partially offsetting investor worries about any single therapeutic area. In this way, Tezspire’s recent data provide a counterweight to concerns raised by the Novartis pelacarsen trial and highlight why some analysts remain constructive on Amgen’s long-term growth prospects despite near-term volatility.
Stock level and investor takeaway
As of the completed trading day immediately preceding the sharp September 8, 2026 move, Amgen shares closed at around USD 437.23 on Nasdaq, with after-hours indications near USD 415.00, illustrating the shift from a period of steady gains into a phase of sudden repricing.Investing.com At that closing level, the stock stood close to, but still below, its 52-week high of USD 447.03 cited in premarket commentary on September 8, 2026, underlining that the latest decline came from a relatively elevated starting point.Yahoo Finance Market capitalization figures around that price point indicate a large-cap valuation in the tens of billions of USD, consistent with Amgen’s role as one of the sector’s biggest names.GuruFocus
For investors, the current situation can be summarized as follows: Amgen combines strong past share-price performance and solid underlying cash flows with an increasingly debated valuation and new clinical and competitive uncertainties in its cardiovascular pipeline. The BMO Capital downgrade to Market Perform at a USD 450.00 target and the Novartis trial outcome act as near-term catalysts forcing the market to revisit how much future growth is already priced in. The key question for shareholders is whether upcoming data and earnings releases will confirm the more cautious stance or restore confidence in the company’s ability to grow into its valuation.
Key data on Amgen stock
- Company: Amgen Inc.
- ISIN: US0311621009
- Ticker: AMGN
- Trading venue: Nasdaq
- Price (as of September 8, 2026, 10:04): 402.07 USD
- Market capitalization: 437.23 USD share price reference used in recent valuation analysis implies a large-cap value in the tens of billions of USD (as of September 4, 2026)
- Sector / Industry: Biotechnology / Pharmaceuticals & Medical Research
- Index membership: S&P 500
